EXPORT CITATION

Chapter-100 Recent Advances in Hypertension Management for Cardiovascular Disease Prevention

BOOK TITLE: CSI: Cardiology Update 2014

Author
1. Gupta Rajeev
ISBN
9789351526186
DOI
10.5005/jp/books/12415_101
Edition
1/e
Publishing Year
2015
Pages
8
Author Affiliations
1. Eternal Heart Care Centre and Research Institute, Mount Sinai New York Affiliate, Jaipur, Rajasthan, India, Eternal Heart Care, Centre and Research Institute, Jaipur, Rajasthan, India, Eternal Heart Care Centre and Research Institute Mount Sinai Hospital Affiliate, Jaipur, Rajasthan, India, Eternal Heart Care Center and Research Institute, Mount Sinai New York Affiliate, Jaipur, Rajasthan, India, Eternal Heart Care Centre and Research Institute (Mount Sinai New York Affiliate) Jaipur, Rajasthan, India, Cardiothoracic Center All India Institute of Medical Sciences New Delhi, India, Eternal Heart Care Center and Research Institute, Mount Sinai New York Affiliate, Jawahar Circle, Jaipur, Rajasthan, India, Eternal Heart Care Center and Research Institute, Jaipur, Rajasthan, India, Eternal Heart Care Centre and Research Institute, Academic and Research Development Unit, Rajasthan University of Health Sciences, Jaipur, Rajasthan, India, Eternal Heart Care Center and ResearchInstitute, Mount Sinai, New York, Affilia
Chapter keywords
Stress management, ACE inhibitors, dihydropyridine, ASCOT-LLA, combination therapy

Abstract

The high-risk individual-based prevention approach is used to assess various risk factors to determine individual risk and then intervene.9 Medical interventions are often required. Controlled BP helps in lowering the burden of CVDs. Primordial prevention strategies focus on the population-wide reduction of multiple cardiovascular risk factors. Primordial Prevention, risk factor control, smoking and tobacco, are discussed in addition to stress management and promotion of physical activity. A number of pharmacological agents are available for BP control. The drugs available for hypertension management for cardiovascular risk reduction include ACE inhibitors, ARBs, CCBs, beta-blockers, diuretics and others. Indications regarding the use of these classes of drugs are given in the chapter.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved